[298] . www.ftc.gov/os/testimony/P859910%20Protecting_Consume_%20Access_testimony.pdf. & www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129385.htm. last visited: 10/26/2014. [299] . www.ftc.gov/os/2003/10/innovationrpt.pdf. , last visited: 10/26/2014. [300] . www.ftc.gov/reports/innovation/ P040101PromotingInnovationandCompetitionrpt0704.pdf., last visited: 10/26/2014. [301] . www.ftc.gov/os/2011/03/110307patentreport.pdf. , last visited: 10/26/2014. [302] . P.M Danzon, A.W Mulcahy, A.K. Towse, “Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement”. NBER Working Paper, No. 17174, June 2011. http://www.nber.org/papers/w17174.pdf, last visited: 10/22/2014. [303] . “Generic Pharmaceuticals”. Daf/Comp(2009)39, Organisation For Economic Co-Operation And Development, 2010, P. 9. http://www.oecd.org/competition/abuse/46138891.pdf, last visited: 10/25/2014. [304] .ibid, P. 18. [305] . WTO; WHO; WIPO. “Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade”. Geneva, 2013, P. 198. [306] . “Antitrust: Commission enforcement action in pharmaceutical sector following sector inquiry”, European Commission, 2012. & “Antitrust: shortcomings in pharmaceutical sector require further action”, IP/09/1098, Brussels, 2009. http://europa.eu/rapid/pressReleasesAction.do?reference=MEMO/12/593&format=HTML&aged=0&language=EN&guiLanguage=en, last visited: 10/27/2014. [307] . Ever-greening of patent. [308] . Patent Clustering. [309] . “Executive Summary of the Discussion on Competition and Generic Pharmaceuticals”. Annex To The Summary Record Of The 121st Meeting Of The Competition Committee Held On 18-19 June 2014, Daf/Comp/M(2014)2/Ann6/Final, Organisation for Economic Co-operation and Development, 10-Feb 2015, P. 5. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DAF/COMP/M(2014)2/ANN6/FINAL&doclanguage=en, last visited: 10/28/2014. [310] . Pfizer [311] . Summary Record Of The Discussion On Competition And Generic Pharmaceuticals, Annex To The Summary Record Of The 121st Meeting Of The Competition Committee Held On 18-19 June 2014, Daf/Comp/M(2014)2/Ann3/Final, Organisation For Economic Co-Operation And Development, 2014, P. 8. [312]. داروی گلیوک (Glivec) برای درمان انواع خاصی از سرطان خون و دستگاه گوارش و همچنین برخی از تومورهای نادر دیگر استفاده می شود. [313] . “Indian Supreme Court delivers verdict in Novarits case”. MSF, 1 April 2013. http://www.msf.org/article/indian-supreme-court-delivers-verdict-novartis-case, last visited: 2015/12/01. & Kaustubh Kulkarni, Suchitra Mohanty, “Novarits loses landmark india cancer drug patent case”.  REUTERS, Apr 1, 2013, http://www.reuters.com/article/2013/04/01/us-india-novartis-patent-idUSBRE93002I20130401, last visited: 2015/12/01. & R. Jai Krishna, Jeanne Whalen, “Novartis Loses Glivec Patent Battle in India”. The Wall Street journal, April 1, 2013, http://www.wsj.com/articles/SB10001424127887323296504578395672582230106, last visited: 2015/12/01. & Frederick Abbott, “The Judgment In Novartis V. India: What The Supreme Court Of India Said”. Intellectual Property Watch, 2013. http://www.Ip-Watch.Org/2013/04/04/The-Judgment-In-Novartis-V-India-What-The-Supreme-Court-Of-India-Said/, last visited: 12/01/2015.